PCOS and Hirsutism

Status: draft compiled 2026-04-20.

Hirsutism — terminal hair growth in androgen-dependent regions in patterns culturally coded as male — affects approximately 5-10% of women, of whom polycystic ovarian syndrome (PCOS) accounts for roughly 70-80%. Laser hair removal is an evidence-supported adjunct to medical management rather than a standalone treatment; the Endocrine Society 2018 guideline treats combined medical + laser as the standard of care for moderate-to-severe hirsutism and laser alone as insufficient because it addresses the existing terminal follicles but not the ongoing androgenic recruitment.

The clinical framework

Hirsutism is defined as Ferriman-Gallwey score >8 (modified mFG; some references use >6 in East Asian populations). Workup: total and free testosterone, DHEAS, 17-hydroxyprogesterone (to screen for non-classical congenital adrenal hyperplasia), prolactin, TSH; ACTH stimulation if 17-OHP borderline; dexamethasone suppression if Cushing features; imaging (pelvic ± adrenal) if rapid virilisation or total T >150 ng/dL (androgen-secreting tumour workup). Source: Endocrine Society 2018, JCEM, Martin KA et al. Confidence: C1.

Most hirsutism is idiopathic or driven by PCOS; adrenal sources and androgen-secreting tumours are rare but worth identifying because they change the treatment plan.

Medical management

The Endocrine Society 2018 guideline supports:

1. Combined oral contraceptive (COC) first-line. Antiandrogenic progestins (drospirenone, cyproterone in Europe, dienogest) outperform older progestins for hirsutism endpoints. Expected reduction: 15-25% F-G score at 6-12 months.

2. Spironolactone 100 mg/day (range 50-200 mg/day) added for moderate-to-severe hirsutism. Expected additional reduction when combined with COC. See ../../shortterm-deep/hormonal-prereqs.md §Spironolactone. Source: Cochrane Brown J 2016 CD000194.

3. Cyproterone acetate as alternative to spironolactone in Europe, Canada, and Australia; not available in US. See ../../shortterm-deep/hormonal-prereqs.md §Cyproterone.

4. 5α-reductase inhibitors (finasteride 2.5-5 mg/day, dutasteride 0.5 mg/day) as second-line or adjunct in refractory cases.

5. Eflornithine 13.9% cream (Vaniqa) as topical adjunct for facial hair.

6. GnRH agonists reserved for severe refractory cases.

7. Metformin is not effective for hirsutism scores alone; useful for the metabolic component of PCOS but not for hair-specific endpoints.

Durable medical response requires 6-9+ months of continuous therapy before steady state is established. Sources: Endocrine Society 2018; SOGC guideline 444 2023; Anti-androgens PCOS meta-analysis, PMC10424142. Confidence: C1.

Laser's role

Laser hair removal addresses the existing terminal follicles — the visible, cosmetically problematic hair — while medical management addresses the ongoing recruitment. Neither alone is as effective as both together. A patient on spironolactone + COC without laser will experience slower hair growth and modest thinning but usually will not achieve cosmetic clearance; a patient who laser-removes all visible terminal hair without medical management will see new terminal follicles recruit and the hair return over 12-24 months as androgens continue to drive vellus-to-terminal conversion.

The combined regimen produces durable cosmetic clearance. Laser parameters for hirsutism follow the standard framework (see ../wavelengths/); the face and jawline are typically treated with appropriate wavelength (alexandrite for Fitz I-III, diode for III-IV, Nd:YAG for IV-VI) at 4-6 week intervals. Session counts may run higher than for non-hormonal patients — 10-15 sessions rather than 6-8 — because ongoing hormonal recruitment keeps producing new terminal follicles. Maintenance touch-ups every 3-6 months are common. Confidence: C2.

Paradoxical hypertrichosis in PCOS

Patients with PCOS and related hyperandrogenism are over-represented in the paradoxical hypertrichosis literature (Alsarhan et al 2025, PMID 40405001 found significant association with irregular menses and family history of hirsutism). The at-risk phenotype for paradoxical induction — Fitzpatrick III-IV, Mediterranean / Middle Eastern / South Asian / Latin American ancestry, face/neck treatment area, alexandrite wavelength — substantially overlaps with the PCOS / hirsutism patient population. See ../complications/paradoxical-hypertrichosis.md for the full discussion.

Practical guidance for PCOS patients planning facial laser:

• Screen for hyperandrogenism as part of baseline workup before starting laser.
• Prefer Nd:YAG 1064 nm or SHR-mode diode over alexandrite for face/neck treatment in this population.
• Use appropriate fluence rather than sub-therapeutic dosing; fluence reduction is not a safe hedge here.
• Start medical management 3-6 months before laser where possible so the endocrine substrate is stabilised before laser begins.
• Have a plan for paradoxical induction — electrolysis as backup for any paradoxically induced residual hair.

Confidence: C3.

Timing of laser relative to medical management

The ideal sequence is: start medical management 3-6 months before laser (to stabilise the endocrine substrate and reduce the rate of new terminal-follicle recruitment), continue medical management throughout the laser course, and continue medical management indefinitely or at least for years after laser completion to prevent rebound growth. Patients who start laser without medical management often see faster apparent results (because the visible existing hair is destroyed) but experience more regrowth and more need for touch-ups over subsequent years. The combined sequence produces the most durable clearance. Confidence: C2.

When laser is inadequate even with medical management

Some PCOS patients have hair colour profiles where laser is ineffective — fine blonde facial hair, red hair, mixed dark-and-pale hair in the same field. For these patients, electrolysis is the only effective definitive method, used in combination with medical management. Electrolysis is pigment-independent so works on any hair colour; for full-face clearance in hirsutism it typically requires 150-300+ hours over 12-24 months, which is a significant time and cost commitment but is the only option when laser does not apply. Sources: Richards & Meharg 1995, PMID 7673501. Confidence: C2.

Eflornithine as topical adjunct

Eflornithine 13.9% cream (Vaniqa) is the only FDA-approved topical that slows facial hair growth and is evidence-supported as an adjunct to laser in hirsutism (Hamzavi 2007 JAAD laser + eflornithine, PMID 17482708). It does not remove existing hair but reduces regrowth rate between sessions, effectively extending the interval at which sessions appear to "wear off." For PCOS patients on a laser course, daily eflornithine between sessions is reasonable if budget permits (~$50-150/month). Confidence: C1.

Psychological and quality-of-life context

Hirsutism produces substantial psychological distress independent of objective hair density; the Ferriman-Gallwey score is a crude measure that does not capture patient-perceived severity. Some patients with mild objective hirsutism are severely distressed; others with higher F-G scores cope well. Treatment goals should be informed by patient-reported quality of life rather than by objective scoring alone. The Endocrine Society 2018 guideline acknowledges this and does not treat F-G score as the sole indicator for treatment escalation. Laser hair removal is a particularly impactful intervention in this population because the persistence of visible hair despite medical management is often the most distressing aspect of the condition.

Confidence: C3.